| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2014.07.002 |
| P8608 | Fatcat ID | release_lwwcfr2l3ncljiofuliebgd74u |
| P932 | PMC publication ID | 4387777 |
| P698 | PubMed publication ID | 25019568 |
| P5875 | ResearchGate publication ID | 263899380 |
| P50 | author | Hedvig Hricak | Q5697714 |
| Debra M Sarasohn | Q57569502 | ||
| Douglas A Levine | Q86514653 | ||
| Yukio Sonoda | Q88607034 | ||
| Pedro T. Ramirez | Q90326369 | ||
| Alexia Iasonos | Q91946576 | ||
| Dennis Chi | Q91946580 | ||
| Ginger J. Gardner | Q91946587 | ||
| Carol Aghajanian | Q91946596 | ||
| Nadeem R. Abu-Rustum | Q99678175 | ||
| Svetlana Mironov | Q117234463 | ||
| Rudy S Suidan | Q117234466 | ||
| Jerrold B Teitcher | Q117234478 | ||
| Revathy B Iyer | Q117234479 | ||
| P2093 | author name string | Qin Zhou | |
| Mario M Leitao | |||
| Masayoshi Hosaka | |||
| Harold Paul | |||
| P2860 | cites work | Cancer statistics, 2014 | Q27861018 |
| Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup | Q30436714 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma | Q33900834 | ||
| Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis | Q33957687 | ||
| Identification of prognostic factors in advanced epithelial ovarian carcinoma | Q34344858 | ||
| Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis | Q34762831 | ||
| CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer | Q35092157 | ||
| A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer | Q36187800 | ||
| What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? | Q36484029 | ||
| Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction | Q36682388 | ||
| Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study | Q36912591 | ||
| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer | Q44461877 | ||
| Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer | Q46170323 | ||
| The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma | Q47228485 | ||
| Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach | Q50160858 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residu | Q53455916 | ||
| Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. | Q53486021 | ||
| A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study | Q57903863 | ||
| Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma | Q70524843 | ||
| Ovarian carcinoma: value of CT in predicting success of debulking surgery | Q72064432 | ||
| The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma | Q72382597 | ||
| A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography | Q73025456 | ||
| Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study | Q73739424 | ||
| A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model | Q80549677 | ||
| A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma | Q83052427 | ||
| Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study | Q83137403 | ||
| The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer | Q83303023 | ||
| Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer | Q84529939 | ||
| An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) | Q84943384 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | computed tomography | Q32566 |
| uterine tube | Q1233836 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 455-461 | |
| P577 | publication date | 2014-07-11 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer | |
| P478 | volume | 134 |
| Q35926352 | A framework for a personalized surgical approach to ovarian cancer |
| Q39831752 | A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: A single-institution assessment. |
| Q40331453 | A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer |
| Q96228870 | A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative |
| Q44223057 | A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer |
| Q55302464 | A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. |
| Q36372816 | A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery |
| Q93026855 | A radiologic-laparoscopic model to predict suboptimal (or complete and optimal) debulking surgery in advanced ovarian cancer: a pilot study |
| Q57164774 | A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study |
| Q54047420 | Advanced Primary Epithelial Ovarian and Peritoneal Carcinoma-Does Diagnostic Accuracy of Preoperative CT Scan for Detection of Peritoneal Metastatic Sites Reflect into Prediction of Suboptimal Debulking? A Prospective Study. |
| Q104062907 | Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events |
| Q26739931 | CT in ovarian cancer staging: how to review and report with emphasis on abdominal and pelvic disease for surgical planning |
| Q38703522 | Can advanced-stage ovarian cancer be cured? |
| Q36834937 | Characteristics of 10-year survivors of high-grade serous ovarian carcinoma |
| Q50978871 | Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. |
| Q50055417 | Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival |
| Q47197542 | Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors. |
| Q89056087 | Correlation of Pattern of Spread and Outcomes in Advanced Epithelial Ovarian Cancers |
| Q38442672 | Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer |
| Q90533388 | Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment |
| Q42362054 | E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness |
| Q60908666 | Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands |
| Q89169298 | Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability |
| Q48008944 | Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer |
| Q39382941 | High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes |
| Q91920046 | Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study |
| Q88015812 | Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer |
| Q87899667 | Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection |
| Q89996144 | Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease |
| Q38569619 | Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients |
| Q53054061 | Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. |
| Q30717971 | Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center |
| Q50054786 | Neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Who really benefits? |
| Q33626973 | Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline |
| Q46759110 | Ovarian cancer: imaging in treatment selection and planning with FIGO update |
| Q89047880 | Peritoneal Metastases from Gastrointestinal Cancer |
| Q57293949 | Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer |
| Q40274564 | Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: An external validation study of three models using computed tomography |
| Q46325180 | Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study |
| Q64935931 | Predictive significance of preoperative CT findings for suboptimal cytoreduction in advanced ovarian cancer: a meta-analysis. |
| Q26828510 | Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care |
| Q37290454 | Preoperative Lymphocyte-Monocyte Ratio Is a Predictor of Suboptimal Cytoreduction in Stage III-IV Epithelial Ovarian Cancer |
| Q91744535 | Preoperative PET/CT score can predict complete resection in advanced epithelial ovarian cancer: a prospective study |
| Q40387712 | Preoperative hyponatremia in women with ovarian cancer: An additional cause for concern? |
| Q92861533 | Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review |
| Q38260301 | Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? |
| Q40042569 | Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group |
| Q38791320 | Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer |
| Q92353188 | Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer |
| Q38364615 | Radical surgery in ovarian cancer |
| Q48248709 | Relevance of enlarged cardiophrenic lymph nodes in determining prognosis of patients with advanced ovarian cancer |
| Q35748533 | Risk stratification and outcomes of women undergoing surgery for ovarian cancer |
| Q40351106 | Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer |
| Q30252115 | Robotic surgery for ovarian cancers: individualization of the surgical approach to select ovarian cancer patients |
| Q26801358 | Role of aggressive surgical cytoreduction in advanced ovarian cancer |
| Q95561799 | Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer |
| Q102209576 | Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study |
| Q61800314 | The ability of whole-body SUVmax in F-18 FDG PET/CT to predict suboptimal cytoreduction during primary debulking surgery for advanced ovarian cancer |
| Q28067698 | The role of surgery in advanced epithelial ovarian cancer |
| Q26750610 | Update on Imaging of Ovarian Cancer |
| Q53330277 | Upping the ante in assessing the feasibility of surgical cytoreduction for advanced ovarian cancer: a modified laparoscopic Predictive Index score. |
| Q35812813 | Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma |
| Q38529445 | Why have ovarian cancer mortality rates declined? Part II. Case-fatality |
| Q38530989 | Why have ovarian cancer mortality rates declined? Part III. Prospects for the future |
Search more.